Skip to main content
GALT
NASDAQ Life Sciences

Galectin Therapeutics Seeks Shareholder Approval to Double Authorized Shares to 250M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$3.94
Mkt Cap
$390.288M
52W Low
$2.025
52W High
$7.13
52W Position info
95% above low
Off High info
45% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

GALT sits 95% above its 52-week low of $2.025 on light trading volume (0.3× avg).

Summary

Galectin Therapeutics' definitive proxy asks shareholders to approve a 100 million share increase in authorized common stock, from 150 million to 250 million, at the December 3, 2026 annual meeting.


Key Events · Corporate Governance and Compliance · GALT

  • Authorized Share Increase Proposed

    Proposal 2 seeks to increase authorized common stock from 150,000,000 to 250,000,000 shares, adding 100 million shares for future issuance.

  • Equity Plan Expansion

    Proposal 3 would reserve an additional 3,000,000 shares under the 2019 Omnibus Equity Incentive Plan, increasing the plan from 10,000,000 to 13,000,000 shares.

  • Annual Meeting Scheduled

    The 2026 Annual Meeting will be held virtually on December 3, 2026, with a record date of October 6, 2026.

  • Chairman's 49.4% Stake

    Richard Uihlein beneficially owns 54,831,388 shares, or 49.4% of common stock, after converting $105.8 million of debt to equity on July 31, 2026.


Analysis · GALT · Life Sciences

The definitive proxy sets a December 3, 2026 vote on increasing authorized common stock from 150 million to 250 million shares. With only about 26 million authorized shares remaining after accounting for outstanding instruments, the company states it needs flexibility for future equity financings to fund operations beyond the next twelve months. Chairman Richard Uihlein, who controls 49.4% of the stock, converted $105.8 million of debt to equity in July 2026, eliminating nearly all debt but leaving the company reliant on equity raises. The additional 100 million authorized shares represent potential future dilution for existing holders, though no immediate issuance is planned.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GALT was trading at $3.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $390.3M. The 52-week trading range was $2.03 to $7.13. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GALT - Latest Insights

GALT
Nov 16, 2026, 8:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.10
Real-time Price: $3.04 info
Change: -$0.065 (-2%) info
Market Cap: $306.079M info
GALT
Nov 16, 2026, 7:50 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.10
Real-time Price: $3.04 info
Change: -$0.065 (-2%) info
Market Cap: $306.079M info
GALT
Oct 02, 2026, 3:53 PM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $3.92
Real-time Price: $3.04 info
Change: -$0.880 (-22%) info
Market Cap: $306.079M info
GALT
Aug 14, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.45
Real-time Price: $3.04 info
Change: -$0.415 (-12%) info
Market Cap: $306.079M info
GALT
Aug 14, 2026, 7:55 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.49
Real-time Price: $3.04 info
Change: -$0.455 (-13%) info
Market Cap: $306.079M info